INVESTMENTS THAT MATTER

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

Across all stages of development, we align ourselves with scientists, entrepreneurs and other investors to develop the next generation of healthcare innovations that will have a positive impact on patients’ lives.

OUR PROVEN STRATEGY

At Agent Capital, we proactively guide biotech companies to milestones and exits.

With a balanced investment approach and a deep understanding of biopharma’s pipeline pressures, we are committed to making investments that move healthcare forward – no matter the stage or investment type.

TYPICALLY, OUR KEY INVESTMENT AREAS OF FOCUS INCLUDE:

Rare Diseases
Oncology
Neurology
Immunology
Learn More

Featured Portfolio Company

Dice Therapeutics

Freenome

Metagenomi

Pliant Therapeutics

ViTToria Biotherapeutics

Dragonfly Therapeutics

Carisma Therapeutics

Skyhawk Therapeutics

Flare Therapeutics

ImCheck Therapeutics

Orchard Therapeutics

Entrada Therapeutics

Zenas Biopharma

Star Therapeutics

Pyxis Oncology

Precision Biosciences

Palvella Therapeutics

View Full Portfolio

Featured News

News | December 19, 2024

Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101

Read More

Press Release | December 11, 2024

Cyrus Biotechnology Announces Potent in vivo Redosability of an Engineered IdeS Protease for IgG-driven Autoimmune Disease, Demonstrating No Anti-drug Antibodies

Read More

News | December 9, 2024

Vittoria Biotherapeutics Presents Positive Preclinical Data at 66th Annual ASH Meeting Supporting its Novel Approach to Engineered CAR-T Cell Therapies

Read More

View All